Valuation
26% of the score
60median 13
Regeneron Pharmaceuticals is valued at 15.1x its operating profit, including debt: an ordinary multiple.
25x
20x
15x
10x
6x
15.1x
Full points at 6x or less, none from 25xfull points
REGNRegeneron Pharmaceuticals
$752.55+32% 1Y
$752.55
$553.3252 weeks$852.16
RyuScore
Seven criteria, each scored 0 to 100 on a published scale, weighted into one number.
RyuScore 65 out of 100, Above average
Today's price. Only valuation depends on it.
Above average. Regeneron Pharmaceuticals scores higher than 77% of the 1,794 companies Ryufin scores.
Carried by return on capital and cycle position, held back by return on new capital.
Healthcare median 27 · all companies 50
Return on capital
18% of the score
98median 34
Over 7 years the business earned 24% a year after tax on the capital it uses.
2%
8%
15%
25%
24%
None at 2% or less, full points from 25%full points
7 years agolatest 12%
Return on new capital
16% of the score
0median 49
Over 6 years yearly profit fell by 9 cents for every dollar earned. New capital earned -17%, and 57% of profit went back into the business.
-5%
12%
-9.5%
None at minus 5 cents, full points from 12 centsfull points
Capital allocation
14% of the score
58median 64
How management spends the money: shares bought back or issued, and whether assets grow faster than the business they serve.
Share countDown 1.2% a year over 5 years: buybacks
775%
-3%
-1.2%
0 pointsfull points
Assets against salesAssets grew 19% a year, sales 11%
3112%
-2%
7.7%
0 pointsfull points
Cycle position
12% of the score
99median 62
Today's operating margin of 25% is 0.71x its normal 35%: below its usual level, with room to recover. Normal is half the 10 year median, half the last four years, so a margin that has held is not taken for a peak.
2x
1.5x
1x
0.7x
0.7x
A trough earns points, a peak costs themfull points
10 years agonow 25%
Balance sheet
8% of the score
100median 50
What the debt weighs against the profit that has to carry it.
Net debt to EBITDAMore cash than debt
100Interest coverOperating profit covers interest 69x
1001.5x
12x
69.4x
0 pointsfull points
Earnings quality
6% of the score
69median 90
Whether the reported profit arrives as cash, and whether the accounts show the usual signs of stretching.
Cash against profitOperating cash flow was 1.09x profit over 3 years
720.7x
1x
1.3x
1.1x
0 pointsfull points
AccrualsCash ran ahead of profit by 1.2% of assets
668%
0%
-8%
-1.2%
0 pointsfull points
How the RyuScore works
Each criterion earns 0 to 100 points on the scale drawn under it, and the RyuScore is their average weighted 26, 18, 16, 14, 12, 8 and 6. Scales bend in the company's favour between their ends, so an ordinary figure is never already near zero. Where a criterion cannot be measured from the filings it is taken out and the remaining weights scale up; a company needs 60% of the weight covered, and always a price, to get a score.
Built from the company's annual and quarterly filings with the SEC and today's share price. Banks, insurers and property trusts are not scored: their debt is their raw material, so these yardsticks mean something else there. Figures as of 2026-06-30, latest annual report FY2025.
Biotechnology
The closest names by size in the same industry